诉讼事件概述 - 针对Organon公司的集体诉讼案件Joseph Hauser v Organon & Co et al已在新泽西州联邦地区法院提起 案件编号2:25-cv-05322 [1] - 诉讼指控公司在2024年10月31日至2025年4月30日期间向投资者提供过于积极的陈述 同时传播重大虚假和误导性陈述及/或隐瞒重大不利事实 [4] 公司财务策略争议 - 被告隐瞒了收购Dermavant后债务削减策略的高度优先性 这直接导致常规季度股息大幅削减70% [4] - 公司被指控在资本配置优先事项方面存在重大不实陈述 特别是涉及通过季度股息进行资本分配的相关信息 [4] 股价市场反应 - 2025年4月30日公司普通股收盘价为每股12.93美元 次日(5月1日)股价暴跌至每股9.45美元 [5] - 单日股价跌幅超过27% 显示市场对股息削减消息的强烈负面反应 [5] 法律程序相关信息 - 利益相关方可在2025年7月22日前请求法院指定其为首席原告 但参与赔偿分配无需担任首席原告角色 [5] - 诉讼详情可通过指定链接https://zlk.com/pslra-1/organon-co-lawsuit-submission-form获取 或通过邮件电话联系Levi & Korsinsky律师事务所 [2][3]

SAN DIEGO, May 20, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Organon & Co. (NYSE: OGN) focused on whether Organon as well as certain of its executives made false and/or misleading statements and/or failed to disclose material information to investors.If you have information that could assist in the Organon investigation or if you are an Organon investor who suffered a loss and would like to learn more ...

公司评级与目标价 - 对Organon & Co (NYSE: OGN) 初始评级为强烈买入 目标价设定为26.4美元 [1] 公司业务与竞争优势 - 公司拥有多元化处方药产品组合 核心优势在于全球女性健康领域的领导地位以及快速增长的生物类似药业务 [1] - 研究机构Moretus Research认为公司具备持久商业模式 现金流潜力被低估 资本配置合理 [1] 投资逻辑 - 预计公司将迎来经营拐点 支持其投资价值 [1] - 研究采用结构化框架 重点识别业务模式可持续 现金流被错误定价的公司 [1] - 估值基于行业相关倍数 强调可比性 简单性和相关性 [1] 研究方法论 - 结合严谨基本面分析与高信号判断驱动流程 避免噪音和过度复杂预测 [1] - 研究倾向于关注未被充分认识的公司 这些公司正在经历结构性变化或暂时性错位 [1] - 目标是通过冷静分析和差异化认知实现不对称回报 [1]

SAN DIEGO, May 10, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Organon & Co. (NYSE: OGN) focused on whether Organon as well as certain of its top executives made false and/or misleading statements and/or failed to disclose material information to investors.If you have information that could assist in the Organon investigation or if you are an Organon investor who suffered a loss and would like to learn more, you can pr ...

NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Organon & Co. (“Organon” or the “Company”) (NYSE:OGN) on behalf of Organon stockholders. Our investigation concerns whether Organon has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On May 1, 2025, Organon reported mixed Q1 FY25 results, missing expectations o ...

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth?The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts for all the Big Pharmas, forecasting, inte ...

LOS ANGELES, May 6, 2025 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of Organon & Co. ("Organon" or "the Company") (NYSE: OGN) for violations of the securities laws.INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to investors. As part of its Q1 2025 earnings release, Organon announced it was slashing its quarterly dividend by approximately 90% despite pr ...

公司动态 - Organon公司因涉嫌违反美国联邦证券法正接受调查 调查重点在于公司及高管是否发布虚假或误导性声明 或未向投资者披露重要信息 [1] - Organon宣布削减约90%的股息 导致股价暴跌超过28% [3] - Organon是一家全球医疗保健公司 主要致力于改善女性健康 [2] 法律事务 - Robbins Geller律师事务所正在牵头调查Organon案件 该律所在证券欺诈和股东诉讼领域具有领先地位 [4] - 2024年该律所在证券集体诉讼中为投资者追回超过25亿美元 超过其他五家律所的总和 [4] - 该律所曾创下72亿美元的历史最大证券集体诉讼赔偿纪录(安然公司案) [4]

公司动态 - Organon因涉嫌违反美国联邦证券法正接受调查 可能涉及高管发布虚假或误导性声明以及未向投资者披露重大信息 [1] - Organon宣布将股息削减约90% 导致股价暴跌超过28% [3] - Organon是一家全球医疗保健公司 主要专注于改善女性健康 [2] 法律调查 - Robbins Geller律所正在牵头调查Organon案件 该律所在证券欺诈和股东诉讼领域具有领先地位 [4] - 该律所在过去五年中有四年被ISS评为证券集体诉讼服务排名第一 2024年为投资者追回超过25亿美元赔偿 [4] - 该律所曾创下72亿美元的历史最大证券集体诉讼赔偿纪录(安然公司案) [4]

会员优惠与投资组合 - 公司提供年度会员折扣优惠 首次会员享有11个月资金保证 [1] - Conservative Income Portfolio专注于高安全边际的价值股 通过期权降低投资波动性 [1] - Enhanced Equity Income Solutions Portfolio旨在降低波动性 同时产生7-9%收益率 [1] 公司研究与投资策略 - 长期跟踪并交易Organon(NYSE: OGN) 与VTRS存在相似性 [2] - Covered Calls Portfolio提供低波动性收入投资 注重资本保全 [2] - 固定收益投资组合聚焦高收入潜力和严重低估的证券 [2] 团队背景与投资服务 - 分析师团队拥有40年综合经验 专注于期权收入和资本保全 [3] - 与Preferred Stock Trader合作运营Conservative Income Portfolio [3] - 投资组合包括两个创收组合和一个债券阶梯 [3]